Go back

Mark Cuban’s Plan to Make Healthcare Affordable

1h 1m 27s

Mark Cuban’s Plan to Make Healthcare Affordable

The U.S. health care system is fundamentally broken by entrenched monopolies, opaque contracts, and broken economic incentives. Mark’s entrepreneurial ventures—offering transparent pricing, direct hospital contracts, local pharmacy access, and affordable drug manufacturing—challenge the status quo by introducing trust, competition, and real-time cost visibility. A key driver of change is AI, which can analyze complex contracts and reveal hidden price inflation, empowering employers and patients to negotiate better terms. However, AI alone cannot fix systemic issues; structural reforms are essential, including mandatory public disclosure of contracts, greater transparency in hospital and pharmacy pricing, and dismantling vertical integration. The future of health care lies in personalized medicine, AI-driven diagnostics, and preventive models where data is used to tailor treatments. Doctors will transition from standard care providers to physician-scientists who interpret individual biological data. Ultimately, sustainable disruption requires not just technological innovation, but policy shifts—such as public funding models, guaranteed stop-loss programs, and consumer access to financial assistance—so that health care becomes affordable, transparent, and patient-centered. The greatest opportunity lies in empowering individuals to make informed decisions, leveraging AI and data to break the cycle of hidden costs and inefficiency.

Transcription

11533 Words, 62833 Characters

English
We are not in an efficient health care market, the economics are broken. One of the many ill of health care is that it completely lacks competitive dynamics just merely by the presence of cost-plus drugs you've actually forced change in the incumbents. United Health, 3000 plus subsidiaries, $150 billion in inter-company transfers annually. There's often times when they will increase premiums, increase deductibles, and at the same time force you into a relationship with the company they already own and you don't know they own them. The ultimate mission is to disrupt health care so that it's affordable again. Is there like some area where you're like, "Why is no one building here?" There's no better time to be an entrepreneur than right now. The biggest challenge and where AI I think is going to have the biggest impact is. Our Cuban has a simple piece of advice for employers trying to lower their health care costs. Take every benefit's contract you're about to sign. Run it through AI and ask where you're getting screwed. In this episode, Julie you and I sit down with Mark to talk about what he's learned trying to disrupt one of the most opaque industries in America. We start with cost-plus drugs, which is grown from 111 medications at launch to roughly 4,000 skews today. Mark explains why he sees trust as the company's core product, how it's expanding into direct hospital contracts and drug manufacturing, and why transparency can be more disruptive to health care than another layer of technology. We also get into AI. Mark argues that it can expose bad contracts and help consumers navigate a system that was almost impossible to understand before. But he's skeptical that AI alone can fix health care when the underlying economics and incentives remain broken. In looking further ahead, we discuss personalized drugs, how the role of doctors could change, and why Mark thinks this is the greatest technological transition he's ever seen. Well, Mark, welcome to the podcast. Thanks so much for joining. Thanks for having me on, guys. Julie, what is struck you about Mark's contributions in the space? What have you always found fascinating about what Mark's been up to, the cost-plus drug and just in general, and why we invite him on to the show? I mean, Mark, first of all, just had the courage to enter into the morass that is healthcare in a way that made such a splash and that many, many people who also are in the privileged position that Mark is in, to just have such a huge audience, have been intimidated to do over many, many decades. And so I've loved watching the market react to what Mark has done in healthcare. I think the one thing that I know Mark, you and I have talked about this in the past, but one of the many ills of healthcare is that it completely lacks competitive dynamics and competitive courses, free market dynamics, all that kind of stuff. And what's been fascinating to watch is just merely by the presence of cost-plus drugs as one example, and we'll talk about others that you've done, too, but just merely by the presence of that entity and what you represent and what you're doing, you've actually forced change in the incumbents that otherwise, even with policy, even with all sorts of other forces, never changed over the course of many, many decades. So that's one of the things that I don't get to see that stuff because I don't talk to those guys. And then, I think to your point, even absent a contract, I think people are recognizing from the demands out of the market that they need to show that there is some pathway for people to get your product, right? And so, perhaps even in the absence of a direct contract, I do hear people talking about your solution. That's great. That's great. It truly does not surprise me when the big three or even the big six use our name as kind of a way to counter the requests and the discussion of pricing because they know that our prices are public, that anybody can take our API and big companies that have half a brain are pulling that data on a daily basis and they're saying you have to beat this price. And so, I can see that, but I've had at least one company and probably more that have said, oh, yeah, one of the big three has told us that you're part of their network and we get your prices where you're cheaper. And we don't have an agreement at all with any of the big three. Mm-hmm. Mark, let's zoom out and take stock about where you're at with the business. You launched in 2022 with a few dozen drugs in April this year. You said you were up to roughly 4,000. You're getting into manufacturing, hospital contracts, potentially AI-based care. When you take stock a little bit of where the business is in the years. I'll give you the rundown. So, we launched cosplaystrucks.com, January 19th of 2022, 111 medications, pure legionaire, and we didn't know what to expect at all. I went out and started talking about it and it immediately blew up, right? And then our volumes there led the manufacturers to expand their portfolio with us and we were able to add additional manufacturers. So now, as you said, we have 4,000 skews give or take and our business every week is up and to the right. Our biggest challenge is just keeping up with it. So that's segment number one. Then the obvious response to mail order is, "Well, I would need to pick things up today." And so we created what's called the teamcubancard.com, I did not name it. And it's basically a discount card that allows you to go to any of the 17,000 pharmacies that have affiliated with us and pick up most of our drugs locally. Because we pay, I'm a big believer in supporting independent pharmacy. So we pay our affiliate pharmacies $12 fill fee, which means that's going to make us more expensive for the lowest cost trucks. Because if you have a $5 stat and plus $12, you're going to get a cheaper somewhere else. But at the same side, if you really want to support your independent pharmacies, you can pick up the cheap drugs. But on the more expensive drugs, the specialty generics, the biosimilars were actually much cheaper. And for things like biosimilars and insulin and things that have cold shipping, it's actually cheaper to buy it and pick it up locally through our teamcubancard. So that's the second stool in what we offer. Third is cost plus marketplace. Well, before I get to cost plus marketplace, let me go back to our Dallas Manufacturing. So a big part of Alex, my co-founder, Dr. Alex Sajmyanski, his original cold email to me was he wanted to manufacture drugs that were generic drugs around the FDA short supply list. Because there are pediatric cancer drugs or things that are widely used in hospitals, Pinouf, Potosan, Epinephrine, this long list of drugs. And we were able to use AI and to use robotics to shrink what would have been a football field or more into 5,000 square feet. And not only that, but we were able to turn drugs every four hours. So we can make a six month supply, turn the line, and then go to the next drug and continue doing, and we sell those products to hospitals and clinics. An extension of that, because we started working on that five years ago, we've been able to take those same robotics and AI and shrink it into a manufacturing plan, if you will, the size of a tractor trailer. And we call those pods. And those pods can be used for anything and shipped anywhere. The government was our first customer. We've shipped the first one here recently where we just got an order for a second, and they told us there's more behind that because if there's an ecological disaster, we can send it to FEMA, if FEMA's around. If there is weather disaster, military disaster, got for a bit, we can ship them there and configure them to make any specific type of drug. So we can configure a pod for sterile injectables, for multiple pods, can be daigy chained together so we can scale. And or you can have one who's being a sterile room and another doing the tabulated work for generics. And I'm not the expert on this, Alex can go into this in precise detail. But the thing I'm most proud of, and actually stat News just wrote a story on this yesterday of the day before, is that we can take these pods and configure them to do N of one therapies so that we can ship the pod to a research hospital. And these pods cost about $20 million, ship it to a research hospital. And if they specialize in any types of therapies for those people that are in the N of one category, they can make it and iterate very quickly there. And then now we're doing these ASO drugs and don't ask me what ASO stands for because I can't pronounce it out of our first manufacturing facility in Dallas. So that's part two. From that manufacturing, we created Cosplus Marketplace. And Cosplus Marketplace takes those sterile injectables we make, and that we also others that we source from other providers or other manufacturers. And we sell them at a Cosplus 10 or Cosplus 12 to clinics, hospitals, providers, whoever want to buy them at the cheapest price. And we literally can save hospitals millions of dollars a year. But our biggest challenge there is we convince the CEOs, but we can't always convince the purchasing people to do it. And then finally, because of my own experiences as a self-insured employer, and going around and talking to hospitals, CEOs and CFOs and learning the relationship with the big carriers, the big vertically integrated carriers, and all the things they like and dislike, mostly dislike. I went to them and said, look, I know you hate the delays, the denies, the pre-os, the late pays, the clawbacks, the fact that your plans or the carrier plans keep on increasing deductibles, turning the providers into subprime lenders, because they have to collect the deductibles before they can offer their care, or before they can get access to insurance money. Knowing all these things, I'd like to work out a direct contract, but I want two things. I'm going to tell you when I'm going to give you an exchange for those two things. When I'm going to trust the doctor, unless it's something crazy, trust the doctor so you're not going to need a pre-author, aren't going to be denials. Now we had somebody who had Munchhausen's disease that required a denial, but other than that, if it's something crazy, I'm going to pay the price that we contract for on time. I'm going to take responsibility for the patient out of pocket, either I'll pay it or I'll take the credit risk for the patient itself, so you're not a subprime lender. And in exchange for all that, I want two things. I want a better price, because you're associated administration and overhead, and Dr. Time is much less your yield is going to be higher. And I want the ability to take the contract we signed, this direct contract between us, public. on costpluswellness.com. So it can act as an open source for all of these contracts so that any employer can use them and any provider can post their contract. And even if you don't want to post or use, you can use them as templates in your own negotiations. Well, I love the last piece, Mark, because I think that was a genesis of our thread back and forth when I published a piece a few weeks ago on what I'm calling like the Great Replacement Cycle of Health Plans. And for, I mean, for so long, so employer-sponsored health benefits is the largest class of insurance in our country. If you think about it that way, so roughly about I think 155 million Americans are covered by an employer-sponsored benefit or more. In any case, it's more than half the country, 60% of the country. And historically, it's been completely monopolized by the Bougas, like these national carriers. And it's been an unaddressable market from a startup perspective, right? The relationships were super entrenched. You needed these national networks to be able to play in the game. And so the starting cost to enter the arena was too high for startups to get into. And the relationships were just too entrenched. Now, the premium increases are just freaking ridiculous. This year, even amongst our startups, some Bougas are forcing 60% year-over-year increases in premiums. It's even worse than you think, you know, not to step in, but because they're vertically integrated. So United Health, 3000 plus subsidiaries, $150 billion in inter-company transfers annually. That would make them number 14 in GDP in the United States among states. And so that tells you how big they are and CVS signals are not far behind. And so there's often times when they will increase premiums, increase deductibles, increase out-of-pocket costs. And at the same time, redirect you or actually force you into a relationship with a company they already own and you don't know they own them. And you talk about, you know, employer-based insurance, particularly those who self-insure, 60% of people who get their health care from companies get it from self-insured employers. And those employers need someone to process all the medical claims, put aside pharmacy, the medical claims. Those things are called third-party administrators. And if they're owned by the big Bougas, they're called ASOs, administrative services only. And those administrators, you know, we hear all the time about the problems with PBMs and how they spread price. Well, on the medical side, it's a million times worse because it's also the bigger chunk of the market. Was that? It's also the bigger chunk of the market. Yeah, of course. Yeah, the medical side is much bigger, you know, 10% and growing versus the other 90%. And what they do is the plans and the hospitals have their own contracts. And the hospitals, enlist their market dominate, have the hate the Bougas in those contracts. But more importantly, whatever that relationship is, the self-insured employer has no idea what the terms of that relationship is, right? Even though it's possible you can go on the hospital and look up the tick file, you know, the transparency files for that relationship and that plan. They're not always correct, they're not always right. But what ends up happening is the price that you're the employer pays, the self-insured employer pays rarely matches the amount that was charged or that amount that was paid to the hospital. So there's a spread pricing there. And to make matters worse, those ASOs that are owned by the Bougas, making them possible to reconcile the numbers so that you can see if you're paying more or less. And they do things, you know, there's these things called 835 and 837 files, which is the data that's sent to the hospital and the amount of money that's paid in response to those claims. And the employers have no access to it. And in many cases, they don't even have access to their own claims. It is just so rigged to your point, Julie, trying to, you know, remove them, disintermediate them is the key, the holy grail, to what's happening in healthcare right now. Yeah. And we're super excited to see just an influx of startups that are now able to go after this market. A big reason why, in addition to all these market forces, and again, like the economics just getting to a breaking point, is the fact that AI can play a significant role in enabling a full stack like health plan offering to be built in a way that reduces all the cruft that you're describing in a very short period of time. But this all comes down to who takes the risk. Well, AI, I'm a huge AI fan, live it, love it. I think it's important on the clinical side. I think it's important on the operational side. I think it's most important short term on the contractual side. But the reality is in a broken financial system, even when you introduce AI into the economics and the operations and the processes, when it's already broken, you can't fix it because you brought the point right at the beginning, Julian, you're 100% right. We are not in an efficient healthcare market. The economics are broken. And you see that because if you don't have price discovery, that's one thing that protects you that keeps you from having an efficient market. But what's even worse, and here's where the market, the economics really start to fall apart and what makes it tough for AI in the short term, operationally and less so clinically. The contracts are so big and so long, the book is through their ASOs get to be contractual terrorists. And what I mean by contractual terrorism, the city of Dallas on their PBM contract, I haven't been able to see their ASO contract yet, 1335 pages. There's no group of humans with enough coffee on the planet to be able to catch everything they try to squeeze by. And so as a result, no matter what AI, once you sign a contract, now hopefully you use AI to prevent yourself from signing a bad contract. And I think that's the low hanging fruit for everybody. But once you sign that contract with terms you don't fully understand and conditions you don't fully, you can't even protect yourself against, they win. There's no AI in the planet that can protect you. And when you try to compete with them on plans, right, that sounds good. And I'm all for it, right, what side cars doing and so many others are doing is really smart. But they're having problems because, you know, yes, the wraparound networks are needed and yes, putting together a network is hard. But those book is have so many subsidiaries, they fuck with you somewhere and you don't even realize it. And that's the ultimate challenge. And that's why I'm so big on the breakup, big medicine bill and going after these companies because I want this to be an open market for every entrepreneur, you know, to use AI in every way possible. And so you went exactly where I was going to go, Mark, which is one of the areas where AI is playing a role for better for worse is that it is, is just shining a light on how broken the underlying system that humans designed is, right? So the whole like prior off bot war situation that's happening right now between here's providers is one of, you know, people blame the AI, but it's actually no, it's like AI is just implementing the existing fee for service billing system to the full extent and showing us how broken that system is. So I'm curious to like what your take is on what's the end state of that? Like clearly your direct contracting methodology. It sounds like is able to reduce a lot of the information asymmetry and contract clarity and things of that sort. Is that what it's going to take? The bot wars in terms of claims and up coding and down coding. That's short term stuff, right? That that's just like, you know, okay, I need to lose some weight. I'm not going to eat, you know, my rice. I'm not going to eat my frosted flakes every day, right? It's nice on the periphery and it's a good short term play, but it doesn't really change everything because AI is a great equalizer. Your AI, my AI, your open, you know, open AI, my entropic, whatever it is, we're going to battle each other out and you might win a couple of winnings out, win a couple of winnings, but they're going to net out at some level. So I don't see dramatic change in the long term. Maybe if you're first in, you can pick up some things and you see some lawsuits and you see some challenges when one side has it and the other side doesn't, but the revenue cycle management on the hospital side is, is pretty darn good. And the book is having, have a big problem in my opinion because they grew through acquisitions. We mentioned these 3000 subsidiaries. That's a lot of silo data. And even though you can try to find ways to get access to claims and specific things that allow you to upcode and they're doing that, it's going to be hard for them to become AI native companies on the book side. And I think over the long term, they're going to be challenged, but all of this starts, and I can't say this enough, all of this starts before you, before those employers sign their contracts. If every one of your portfolio companies said, you know what? I'm going to run my existing benefits contract. If I have a broker, if I have a consultant, if I have TPA, if I have a PBM contract, I'm running my existing contract through AI and I'm asking, I'm using a prompt that asks a single question, where are they fucking me over and what should I do about it? And within 30 seconds, you're going to see, bam, bam, bam, bam, bam, bam, bam, bam. And the things I've seen running through contracts, because let me just tell you how much I love AI agents. So I used them all. I used Rockbot. I used Eric and I are NBA fans. And so I got the Luca Docchicks plan because it's $77.69 or something. I'm like, this is brilliant. Rockbot's $77.00, the Luca plan. I got you. And then I have the Gemini plan and then I have Open AI's plan, et cetera, et cetera. And I used the agents and instinct to And I use the agents and I say, "You go out and find me every state entity organization enterprise that has an open records opportunity." And I want you to find me every single contract, RFP, whatever it is you can find from those entities. And I want you to write the letter to request it, put it in an email, put it in my draft, let me personalize it some, tell me when it's there, and I'll hit send. And it's amazing, right? Stump that's always been at the bottom of the list that I always wanted to get to, but never could. Now it's just like, this stuff is coming, so I put it up on Google Drive and each of the different LLMs has access to it. And I just tell them all, every time there's something new loads on the drive, you go through, you tell me, you give me the good news, you give me the bad news, you give me what should be done, and then you give me the simple version so I can send to the company or, you know, school or whatever it is. Bam, bam, bam, bam, bam. And that's where I get to see all these contracts that the big three on the PBM side and the book is on the ASO side are signing. And so I get to see specifically how all these enterprises are getting ripped off. These school districts, oh my God, cities from Denver to Dallas to Fort Worth, unions, I mean, and if you think about it, again, going back to your perfect point, Julie, is if 67% of the employers representing 67%, 160 million plus Americans actually did one thing, one thing, ran their contracts through AI before they signed them and negotiated from that, the entire system for the big bookas and big PBMs and all their subsidiaries would collapse. The cost of healthcare in this country would drop like a rock. And so when I go and I talk to employers, when I go talk to investors and talk about their portfolio companies and they're like, do we need less of a slation? Do we need this? That I'm like, no, you need to be smart and do your job and bring in somebody that I call a healthcare CEO or CFO whose only job is to manage the contracts and everything associated with it. And you will find that your healthcare costs will go down. And then once we get you there, then we can talk about carving out for direct contracts and doing all these other things. Immediately, I like, there's a couple public companies that I told to do this and came back to me and were like, oh my God, we had no idea how badly we were ripped off. And I'm begging them to mention it on their core Leonies conference calls and they won't do it because they still have to do business with those bookas even though if they left them for whatever reason. And so if we just do that one thing, run the contracts, literally, if you have more than 1,500 employees, the quickest way for, or members, I should say, the quickest way for that startup, that tech company, maybe depending on how bad you ripped off into the millions or more, is to just do what I just said, run your contracts through AI. Yeah. Mark, maybe zoom me out. Can you share more about sort of the grand vision for the business if you years out and maybe how do you think about sequencing to get there? So a couple of things. One, I mean, the ultimate mission is to disrupt healthcare so that it's affordable again. And I'm a fan of universal healthcare, but you can't get to universal healthcare until you have correct data and people can make decisions based off of real data. So that's bigger system. Whatever direction it ends up going, I just want to disrupt healthcare so that when people think about the economics, it becomes, okay, I know exactly what's going on. How we get there more education than anything else, like I mentioned before, in terms of the business, the cost plus drugs, look, somebody could come along for the retail site and say, we're going to do cost plus 1%, okay, trust is still our primary product. That's what I try. We don't spend any money on marketing or advertising. And when we first got started, all the people who came from farming said, oh, you're going to get killed. I'm like, no, you know, people are going to tell others how much money they say. And then they're going to trust us. And that's the one thing missing in all of healthcare economics trust. And so once we gain their trust by doing exactly what we said, by being fully transparent, only having to set mark up a 15% will garner people trust. So that'll protect us elite to some level. But the grandiose vision, those pods I told you about that sell for $20 million. There's good margin in those. And we think we can sell within two years, a couple hundred a year, within five years, a couple thousand a year. So you give me, you know, a thousand pods to sell at $20 million each. We're going to be doing really, really, really good. And it'll completely change healthcare because we can daisy chain those things. Like literally, we could manufacture a tablet of generic drugs in Dallas, Texas, using these and make them for less than we pay India, the manufacturers we partner with in India. Now we don't go for the cheapest price. We go for the best manufacturer. So we pay a little bit more, but still we can make it for less. The only thing holding us back is that for each generic, we have to fill out, we have to apply for something called and another new drug application. And each one of those things costs $365,000 plus other fees. So you want to do a thousand of them, that's $365 million plus all the cost of the pods. We're trying to say, look, we truly want to bring manufacturing and on short for medications. We're here for it and we can do it. You're already working with us in other areas. And so we think we'll get there as a big part of what we'll do. And we've already planned so that on costplusdrugs.com, we'll put a little bit of a little American flag when something is manufactured by us here in the US. But that's probably two years away just because of all the work we have to do with the FDA. But that's the big picture. If we're selling $20 billion worth of pods a year, watch out Elon. So is your view that as we look out in the next few years, no matter how good the technology gets, it's not going to disrupt healthcare on its own and that there needs to be other more structural changes that need to happen. Yeah, there's regulatory capture and their scale capture. Right now on the economic side, it's all scale capture. And when you listen to the court of the audience conference calls or read the transcripts for all those big, vertically integrated companies, they talk about technology. But the one thing they never say is this is going to translate into lower costs for employers and patients. They always say this is going to improve our earnings. You know, we're going to return more to shareholders. We're going to buy back stock. And until I'm able to educate all these employers, right, they're going to keep on making it nearly impossible, which is why, you know, when Julie talked about earlier about CVS, why I mentioned we don't deal with any of them directly because we have to work outside of them because otherwise you fall into their trap and they gave me with their contracts. Mark, what do you, in all of this, you know, you're talking a lot about structural things, but there is a reality of what you just read earlier, like AI will change the nature of people's jobs in this industry, what a bit. What do you think is, I've heard you talk a lot about, you know, how do we sort of future prove for, you know, young people with a talent and, you know, what is being like sort of career ready look like in this day and age? What do you think that looks like for healthcare? Like what does the workforce of healthcare look like in the next five years? I mean, it looks the same as any other industry. You have to still hire entry level people because no matter what the model is, the minute it's released, that's it, right? It's behind. It's behind. And so there's latency associated with every model. And so you need people who are aware of everything that's going on that create context and deal with the models, be the human and the loop, understand the consequences, et cetera. And you need those people to grow with the organization over time so that all, as all these things changed, they've seen the history of the implementation and they can bring value to the organization. So that's part one. And just get rid of all entry level positions. Part two, you have to enable those people and everybody else, white collar oriented, how to use AI because AI doesn't replace jobs. People who know how to use AI replace the jobs of people who don't know how to use AI. So that's part two. And then part three is the bigger picture stuff. The first step to that is trying to educate the C suite on how AI even works. Teaching them how agents work. Teaching them how to use a model. Teaching them the difference between open source and closed models and the things you different things you have to do, helping them understand the latency of a model that this brilliant conversation that three of us is having is in no model anywhere and won't be until it's published. So if we say something that we can all go out and use, the models are all behind and AI is all behind. So that's a given. And of course, LLMs are text in some pictures and don't deal with all the real world things that are going on in video. So you have to be able to understand as a CEO and in the C suite, how all those things impact your company. Once you get a good grasp on that, then you just start fooling around, right? Because there you can just find new ways for things to happen that benefit your customers or create new opportunities. And that's the brilliance of AI, right? AI is not smart. It's, you know, it's book smart maybe, but it's not street smart. It's not, you know, entrepreneur smart. You've got to have somebody there who guides it and helps it. But until you have a C suite that understands how it works, it's going to be very difficult for that organization. I mean, I literally sat with the head of a consumer food company. And he was talking to me about acquisitions. And this was months ago. And he was like, yeah, because of GLP ones, yada yada, yada. And I'm like, okay, well, let's do this. Let's take your number one product, your cookie, right? And I'm going to ask Jackie PT to create a competitor that is more GLP one friendly and will be priced lower. And I want a full bill of materials. I want sources, everything, a manufacturing, what I have to do. And in about three minutes, we got back to and he was like, oh, shit. You had no idea. Now, if you have no idea, that's a question you can ask an LLM. You don't have no idea on how to enable your company to use AI. And that, to me, is the greater, greater struggle for most organizations. Now, for entrepreneurs asking that question and trying to implement, no matter what it is, there's no better time to be an entrepreneur than right now. There will be the trillionaire in the basement. There will be somebody who puts out their own agents swarm, but does it on a entrepreneurial basis. Now, there's still challenges, particularly for agents. So agents don't see social media posts. They can't review them, right? And it's hard to get transcripts for any material amount of them. They can't watch ads or see ads. And so if we're moving to an agent-driven economy for individuals, there's going to have to be a lot of changes that occur in how we communicate commerce to those agents. Like, literally, I was fooling around with one of the guys in my company and we created this thing and you can go check it out. It's not truly active. It's called agentfeeds.dev. And the whole idea is you take the transcript of your posts and you just put it into agentfeeds.dev and then you copy and paste it for anybody can copy and paste anybody you follow into their agents. Hey, follow all the fees for this and it takes all the ads and gives you all the information you need. So your agent is more up to date on those categories or whatever. You're going to see an explosion of those types of things, but we still have to get through trust and all the things we all know about AI and the issues we all know about AI. But in terms of opportunities going back to healthcare, the biggest challenge and where AI I think is going to be have the biggest impact other than clinical is by patients by consumers. And being able to look at the things that you are given on the economic side, the benefits bill, the EOB, the explanation of benefits. And here's where I think consumers will get the greatest benefit. So right now, there's terror in, I don't know, half the country, right? 40% of people in the country can't afford a $400 emergency bill. And so what I always tell people is before anything happens, go into your favorite AI model and say, get me a list of all the nonprofit hospitals. Go to go to them and ask them what their financial support services are because all nonprofit hospitals have to have financial assistance programs. And some of them are really good. And for some people, you're better off, and I don't want to make the decisions for people, but you can ask the questions of the AI to say, whatever my insurance plan premium was going to be, I'm going to put it in a money market fund and let it collect interest because I've already discussed my situation with the local nonprofit hospital. And I know everything there is to know about their financial assistance plan. Now, those financial assistance plans are created and the pricing is a reference price to the federal poverty levels in most cases, but it can go up to 600% of federal poverty level, which can be over $100,000 for some families in some states. So patients slash consumers slash families understanding what their options are and how to procure those options from particularly nonprofit hospitals is going to be enormous. If I was going to start a company in this space, I would go to every nonprofit hospital and set up a plan that post agents that I enable people to use. Hey, if you're concerned about how you're going to be able to pay for your bills or your family bills and you don't have much money in the bank, whatever, you're making under X number of dollars, copy and paste this into your muse or into your dot or into, you know, your cloud cowork, whatever it is. And it'll know to come here to us and ask questions. And so when I talk to the heads of hospitals, I'm like, you don't understand, you guys suck at marketing. You are dependent on the bookas and their plans and being part of their network to feed you patients. That's ridiculous, right? If you make it easy for people to use your financial assistance programs, maybe go to a local bank, maybe show people how to learn, use stop loss for smaller, medium-sized companies. So many options for them to use it to make things better for patients, because that's really where the big disconnect is. You can offer better plans. You can use technology to reduce the price and become more efficient in how you create a network where negotiating direct contracts, but until the end user truly embraces it and knows how to use it, there's going to be challenges. But all of us at some level, just like we learned to use spreadsheets back in the day when we thought it was too complicated, I'm old enough to remember when people thought spreadsheets were hard, you know, and you had to explain to them and they had to pay $500 per Lotus one, two, three. But the same thing is happening now as we go through this transition. And people, yeah, there's a lot of people who are anti-AI, but there are a lot of people who are anti-calculators, anti-everything. That's just a matter of time. But once you get the way you get them to overcome AI is of their fear of AI is to show them how these are the things that can really benefit you and protect you and reduce the inherent fear that you have in the event that something goes really, really wrong. There's this famous Aaron Schwartz quote from many years ago, you know, information wants to be free. Yeah. And I know in healthcare, in a previous conversation, you've been a bit skeptical that that will happen because as you mentioned, there's a lot of silo data and there's a lot of strategic reasons why that data is that is their advantage to some degree. And so I say that to ask you, what do you think the ultimate impact of the frontier lab, you know, open AI and thropic have very big ambitions in the space, the them or others will be in reshaping healthcare or sort of, you know, exactly. I'll tell you exactly. And I'm selling my own book here a little bit. The cost of designing a drug personalized to you after reviewing your DNA and knowing everything that it knows will start approaching zero as the capabilities of models go up. Right. We talk about GPUs and how they'll get faster. The networks behind them, the power required, but it's the algorithms that are going to change everything and make them more efficient. Right. And we don't even know what the speed of improvement are going to be on algorithms. But at some point in time, whether it's five years, 10 years, 20 years, they're going to take something from Eric Julian Mark and they're going to say starting with over the counter because if you think about it, right, you walk into a drugstore, you get this, you know, excuse me, whatever, Advil, Tylenol, right, ibiprofen, and we all think it's going to impact us the exact same way. And we have to experiment to see how it impacts our body, the body makes no sense whatsoever. And so as the processing power and the analytic power of these models from the frontier models gets better, they will be able to really, truly personalize over the product, over the counter drugs without a lot of the misogyses you have to go through to try to figure these things out. Right. And now all of a sudden, if here's my personal ibiprofen, here's my personal dose or mixture of whatever, these over the counter drugs, bam, you start to change it. Then you get into, you know, making other drugs that are personalized for you. Because again, the fact that we all take eloquence and decide between eloquence as a relto or a warfare makes no sense whatsoever in the big scheme of things. And so being able to take those things and personalize that medicine, and what I have told two of the frontier models, I said, if you really want to be smart, you take your $20 or your $200 subscription and you include that service once it's available. Because your marginal cost for doing this at that point in time, look, the inference and everything that has to happen just to respond to a request today, expensive like this, right. Coming down very quickly, but the same thing is going to happen for this type of personalized medicine. Initially, it's going to be enormous, but as we understand the human body more and understand all the variables in our body, more in our brains more, et cetera, and understand the medications and figure out how to do the end of one for everybody, it will be part of a normal subscription because there's no reason it should be how expensive is 23 of me. You pay $99 or less now to get your DNA looked at. And so maybe I pay $99 up front. I give them my DNA if I'm willing to do that, obviously for privacy concerns. They store it. They continue to bam, bam, bam, bam, bam, bam, bam. Maybe you want to know what could be wrong. Maybe you don't want to know what could be wrong based off of your DNA. But if something does go wrong, they have access to all these drugs, all these opportunities and the ability to create them in real time and selling my book. We want our pods to be right there to be able to manufacture them because we're the only ones capable of doing it. And I don't see that changing for a long time. I think one of the things also marked that people probably don't appreciate as much as they should in that context is that as that happens, is what you just described happens and as drugs become just better products for like every individual in the country or in the world. That is actually one of the most disruptive forces for care delivery, right? How much of health care is actually the job of the doctor helping patients figure out why a drug doesn't work for them and calibrating and doing metretration and changing behavior to make your your life work for the drug as opposed to the other way around. And so that's something that I think, you know, because of that latency I mentioned earlier, you're still going to need doctors. If Mark walks into the hospital and I just tried this new personalized medicine and I just start puking my guts out. Yeah. You can have it on video, right? And you can have a robot there say how do you feel Mark, right? And the terminator might walk in and say your time is up. I don't know. But, but I'd rather have a human there with all five senses being able to take a look and ask questions and see the crime mom or the crime son or child or whatever and be able to include that in the context. And so I don't think ever that will replace doctors and we shouldn't even try because and you know, you guys know how adoption of technology is particularly for this. You still have to know the questions to ask. You still have to know what the variables are that matter versus the ones that don't. You still have to realize that even as processing costs drop towards zero, hopefully at some point in time that, you know, there's still a cost associated with it, even if that cost is only time. And so, you know, you need somebody there who's been educated in all those pieces. I think to your point, Julie, where things might change dramatically when it comes to the role of the doctor is how they'll be trained in medical school. They won't be taught the exact same things. They'll have to learn how to use open evidence or whatever else is available out there to and how to extract information. Even if it's just that DNA information and understanding what's in there and what the model thinks about it and being able to translate that to the person because, you know, effectively in order for this to work perfectly, everybody has to have their own model. And that's going to be difficult for everybody. Even though there's going to be millions or not hundreds of millions or billions of models created and supported over the next years and plus on top of that, IP becomes a totally different problem that gets introduced into this equation and process because, you know, up till recently, it's been published or perished. And if you're a doctor and you create something, you want everybody to happen, maybe you can even license it and make some money off of it. But now, you know, if you try to patent something every 12-year-old is saying, hey, look at this patent, change it just a little bit and make my own patent, right? Or if it's, you know, a new procedure in healthcare, you know, you might say, no, you have to come to my model and you have to pay me $9,999 every access, right? Or to use inference, you know, you're going to use this software that I require because nobody's going to give away that IP for free. And that creates a lot more problems. I think part of the underpinning that a lot of AI entrepreneurs have is that going back to Eric's, that information wants to be free. The information with may want to be free, but the person who owns the IP feels differently. And so that's going to change how we interact with models. And, you know, we can argue about, you know, front ends that choose which model is least expensive to answer the question, but we haven't had the discussion on where we find the IP that's needed to either train that model, post train that model, you know, rag that model, whatever it may be, if that person isn't making it available, but it's absolutely required. Does that make sense to you guys? Do you guys think I'm an idiot? You know, I think it's really interesting because it also brings up the point of like, what is the role of the doctor in the future? So number one, I agree that actually, I think we're going to need more doctors in the future because as care advice becomes more abundant, more people are going to demand healthcare actual like real life healthcare services. And so we're going to find we actually need more doctors. And there's certainly to be said about what you what you're describing as like the role of the doctor today is very wrote, right? It's kind of like these are the tasks you got to do these quality measures. It's like you like barely need to use your brain honestly for a lot of the things that doctors are asked to do in the traditional healthcare setting. And what you're describing is like what if like the paradigm moves towards physicians are actually like more physician scientists, right? Like it's actually their job is to take like the bleeding edge of information that we may not know at population scale yet. But on an individual basis, they're at the tip of the spear of collecting novel data, generating novel insights about how people are reacting novel data, but definition, stimulating job description to me. Yes, yes, because by definition, you're exactly right, right? novel data equals person. Exactly. And with like novel data, we're going to have lots to do monitoring, you know, like the blood pressure is the one that like we always talk about is where, you know, it's kind of the same principle as what you're saying. The fact that we take our blood pressure like once a year is kind of ridiculous because it changes me. Not me. I got this shit right here. You're putting an edge. And you know, but soon we're going to have wearables that are just measuring it in real time. Yeah, sure. And like you'll have a much more precise understanding of how you're responding to different therapeutic interventions and even like diet and exercise and all that kind of stuff. And you know, that's going to be just you know, you bring up a good point in terms of novel information. And that's everybody in terms of finding jobs, right? You're going to need AI translators for people who may not keep up with these things. You know, regular people that are in wherever in this country or in the world who just, you know, want to live their abundant life whatever that may be. And you're going to need people who are going to be the translators for what's novel about this circumstance or this individual and how do you, you know, make it valid to AI and the output of the AI valid to the novel to the individual. That's going to be a job. And it's going to be very difficult to extract everything from an individual that the AI is going to need. And you're going to have need to have a person. I think they're to do it. Maybe somebody envisions a humanoid robot that is going to ask you those questions and somebody's going to be comfortable. I don't, I don't think I don't think that's going to happen. Yeah. By the way, I don't think I've ever heard you talk about another set of entrenched incumbents, which is the EHR companies. Uh-huh. What's your, what's your theory of the case there on how that market changes or evolves or doesn't in the age of AI and what that looks like in the next few years? Honestly, I don't know. You know, the EHR is dominated by the epic and it's their world, you know, and so I've just kind of deferred to them and tried to stick where I can have an impact because, you know, we partner with them. We think offering pricing, particularly pharmaceutical pricing at the point of script where the doctor is there offering them different options. Yeah, exactly. Exactly. Exactly. That big in Amazon, etc. So I think that's a big plus. And I think that's needed. But in terms of their actual business and words disruptable, I'm not really the one qualified for that. Okay. My phone with, by the way, with that announcement was that they, I love that they announced it. And then they said it's not going to be available till May of next year. And I was like, why? Yeah, I know. I nothing to do with that. That's difficult in this industry, right? Yeah. Do you guys think that in 10 years, uh, you know, healthcare is still going to be a fifth or a sixth of whatever it is now of GDP and that there's kind of this just sort of terminal, as it's sort of terminal state where there's just, you know, way more demand than, um, then sort of, you know, we can supply and just as it gets easier, as it gets more efficient, we're still in as GDP grows, you know, even 5% a year. Hopefully it's at some point where our demand is still going to just cap it, you know, one fifth of the economy. I do. Yeah. The value that we get out of that spend should be, well, the value to get out of the people will increase because they'll be healthier. Yeah. So there's a difference when it's helped, when it's sick care, right? There's a lot of people refer to, um, versus when it's keeping people healthy and they're more productive and there's less downtime and, you know, they're smarter because it's easier to learn, et cetera. Um, so I think we'll get greater productivity that are more than account for it, which we don't get now. Zooming out of it, you know, Mark, we both, we have a mutual friend who is a very prominent pollster. I won't out of here, but he, um, he, he, he, he believes that, or he's done some work to indicate that, um, if you ever ran for office, he thinks you could win. Now, of course you, you said you never, you'll never run, um, so we're just speaking hypothetically now. But if, if you were president or if you were advising the, the next president, I'm curious how, how you would, um, you know, think what is the leverage to most address sort of our health care challenges? And then I want to hear your, your broader, uh, you sort of, you know, policy positions, it's really easy. It's the same thing I tell states, you know, that I've testified for one, make all contracts with anybody who takes taxpayer money, public, no redactions, because the minute that happens, you start to have an efficient market and the cost go down to make it so that anybody who can find a better price for less than their current out of pocket with their plan, make it apply to the deductible, allow it to apply to their deductible. Eight states do that at some level already. Um, three, for nonprofit hospitals, require them to publish their entire general ledger down to each detailed entry and all their procurement, um, receipts and, and requirements, right? So that everybody gets to see it. It's our money. We're the taxpayers, right? For instead of, um, current insurance plans the way we have them, 72% of those big carriers, um, revenue comes from taxpayers. They don't take risk anymore. They offer it, everything's an arbitrage for them. So knowing that, we also have to consider that the one debt we never pay off till the day we die is our insurance premiums. Think about that. Whether it's Medicare, unless you're on Medicaid, right, you're paying till the day you expire. And when you need it, you have to fight for it in the current system and probably foreseeable systems. To me, if we were able to create a program where you just deposited what would be, let's just say, how much you'd pay for a premium under the an ACA silver plan in your state. And we just went and did a deal with the bank and we said, okay, in Texas for a family of five, it's $2,100 at your income, right? So you just keep on depositing $2,100 and it crews and you own it, but it has to be deposited if you want to participate in this program. And then if you have a medical incident or pharmaceutical incident, right, you can take that money. If it's not enough, we've worked out a deal with the bank where two things happen. One, the bank will loan you money up until a point where a stop loss kicks in, which means we're going to take part of that money you deposit and use it for stop loss coverage. And two, the federal government or the state is going to guarantee that loan to you so that the provider is not out. And we're still going to deduct it from your payroll so that you pay it back. And if you're lucky and you never have an incident and you get to save all that money when you turn 65 and go on Medicare, you just get all that money and all the accrued interest. Because if you think about it, the federal government will cover or guarantee your student loans, they'll guarantee SBA loans, they'll guarantee home loans or give you a down payment. We'll guarantee all these things, even agricultural things. But the most important thing covering our healthcare, good luck. You're in a bad accident. Good luck to you. And we'll maybe push it off to the hospital as they have to take you in. So I would create a plan that says you have to deposit this money. The bank will have a guarantee, just like a mortgage, whatever, will loan you this money. And then we'll have federal stop loss programs above some amount, 40,000, whatever it may be. Now all of a sudden, buy by insurance companies. Now all of a sudden, you're not fighting back because it's your money to spend as you choose. Now, we'll have to set thresholds on where and how you can spend it. So you don't just go give it to your cousin Billy who said he's going to fix your, fix your broken toe, right? But within those constraints, I think now all of a sudden we have a better system. So that's what I would do if I was advising in terms of healthcare. What about, you know, one of your gifts is storytelling and marking more generally, what about the AI industry in terms of, obviously, AI is uniquely unpopular in the US. If you were advising, you know, open AI, if you're advising a thropic on how to sort of change those numbers, and then there's the whole sort of data center sort of saga. I'm curious what your advice would be to the broader AI industry. I've had these conversations with them and I told them they're idiots. You know, because what controls how every, pretty much everybody in this country thinks right now, social media algorithms. Literally, I was having a conversation with a 20, 23-year-old friend that I work with. And we're talking politics. We're discussing who we voted for yesterday and how and why. And I said, what about your friends, the other 23, 24-year-olds? And they said that their friends didn't even know, living in Texas. Didn't even know who Ken Paxson or James Tyler Rico were. Right? Which is insane in my mind, right? Insane in this person's mind, but it reinforces the fact that you get more of what you seek via algorithms. And if you really have the best AI, you should be able to not only reverse engineer those algorithms, but put together a marketing program because you sure tell everybody you can do marketing programs through, you know, your bots, your botter, your daughter, whatever, and really start marketing there. Because this applies to politics. It applies to AI. It applies to everything in this country. The divisiveness. We all have our unique AI feed in the social media platforms we use. And those platforms don't give a shit what it feeds you within some minimal constraints. And so everybody looks at the world differently. The days, particularly for younger people of thinking, you know, just by more ads and ruin our football games and our basketball games and everything's fine, you know, maybe older people vote more and that's maybe why, but it's useless when you're trying to change hearts and minds about AI specifically. Even though the irony of it all is that the AI behind the algorithms that's ruining everything. But as long as section 230 is there, we are where we are at. And as long as, you know, unless we take an Australia type approach, some states type approach of 16 and under, then my, what I told them specifically, you need to use your AI to segment everything and figure out the best way to put together marketing promotion. And however else you want to do it, do it like the Russians do it. It doesn't matter, right? Because that's what's at stake for you. But people, you know, data center hate is just a proxy for not being able to understand AI. And not all, no, all the pieces are not on blame people at all, right? And just like employers have been really dumb with their healthcare benefits. A lot of communities have been really dumb with the deals they've negotiated for data centers, you know, and they've fallen for the contractual terrorism in a lot of cases. But, you know, to me, educating them about social media and legislate and educating our legislators and whoever's president about social media because I don't think they truly understand the impact that we don't all read the same newspaper, the same magazines, look at the same websites, watch the same news shows. We all have our own unique TikTok feed. Your feed is not like mine. Like the best way to find out about your kids is just look at their social media feed. Like my 17 year old son, it's basketball, basketball, basketball. Now I'm starting to see a little bit of politics pop up, but then hot girl, hot girl, basketball basketball, car, car, car. And I'm like, okay, I'm a 17 year old guy, right? But until the big frontier models understand completely that they have to figure out how to become part of everybody's feed, they're going to be putting out all these position papers that are useless. Yeah, no, I mean, Mark, we agree with you that what you said earlier about this is like the best time to be alive and an entrepreneur. And so many things that again, we're intractable, historically, are now all of a sudden addressable. Is there an area of the market and you meet a lot of entrepreneurs and see people building in all sorts of areas of the world? Is there some area where you're like, why is no one building here? That you think is still a white space opportunity for entrepreneurs? All of them. You know, seriously, when I go talk to kids, and I always tell them there's going to be two types of companies, those who are graded AI and those who have gone out of business. And if you take the time to learn it, and then there's two types of people and how they use AI, those who use AI to learn anything and those who use AI so they don't have to learn anything. And if you're one of those people who uses AI so that you can learn anything and you realize what type of companies and problems aren't being solved by AI, don't be shy to just talk to your AI. You know, and I say it is not just a kid's to 50-year-old, 60-70-year-old entrepreneurs. The biggest challenge right now with people entrepreneurs using AI is the comfort level of talking to your AI, whether it's by voice or typing whatever it is because there's still a lot of hesitancy. You know, just like back in the day, those first spreadsheets, people still had their ten key add-in machine and they would check it to make sure the spreadsheets were right. You do have to check the output but you have the opportunity to take the output of GROP and put it into chat GPT and the output, like when I go through all these contracts I was telling you about, I start with one and said, "Hey, one of your peers came out and said this about this contract. What do you think?" And spend a couple hours. That's all young entrepreneurs. So when you ask me is there one thing I truly believe it's everything. Everything will change. This is the greatest transitional technology we have ever seen. And I've been around for all of them, right? And this blows them all away. The hardest part is just going for it. And that's where Silicon Valley and you know, kids from the Bay Area, I think have a little bit of an advantage because they see their parents and friends in the culture there as well. Go, go, go, go, go. But I think the rest of the country and the rest of the world, once they get that confidence level, you're going to start to see businesses we never imagine pop up because we're not seeing that. Yeah, you know, we're not seeing companies where it's like, "Oh, what is that? You know, why are they doing that? You know, what is the opportunity there?" And then they realized it before we did, right? It's kind of like Friendster, you know, first like, "Well, what was that?" And so I think the biggest thing to focus on if you're, you know, looking for something is ask anything. I mean, I do it all the time. It's just like, what do you think about this? What do you think about this? You know, I've held phones up next to each other and take the output and have them to have a conversation with each other. So I can listen in. Don't be shy about using AI and things that feel really uncomfortable and weird because that uncomfortableness is probably the path to something that is groundbreaking and game-changing. That's it. That's a great note to wrap on. Mark, thank you so much for coming to the podcast. It was fun. Thanks, guys. Thanks, Julie. Thanks, Eric. Thanks for listening to this episode of the A16Z podcast. If you like this episode, be sure to like, comment, subscribe, leave us a rating or a view, and share it with your friends and family. For more episodes, go to YouTube, Apple podcast, and Spotify. Follow us on X, A16Z, and subscribe to our substack at a16z.substack.com. Thanks again for listening, and I'll see you in the next episode. As a reminder, the content here is for informational purposes only. Should not be taken as legal business, tax, or investment advice, or be used to evaluate any investment or security and is not directed at any investors or potential investors in any A16z fun. Please note that A16z and its affiliates may also maintain investments in the companies discussed in this podcast. For more details, including a link to our investments, please see A16z.com forward slash disclosures. [BLANK_AUDIO]

Podcast Summary

Key Points:

  1. The U.S. health care market is economically broken, lacking competition and transparency, with vertically integrated giants exploiting systemic inefficiencies.
  2. Cost-plus drugs and direct contracting have disrupted incumbents by exposing pricing opacity and forcing price transparency.
  3. Mark’s businesses—offering drug pricing transparency, local pharmacy access, and in-house manufacturing—aim to decentralize control and reduce costs.
  4. AI is a powerful tool to analyze contracts, uncover hidden price inflation, and empower consumers to negotiate better terms.
  5. Structural change, not just technology, is needed
  6. The future of health care involves personalized medicine, AI-driven diagnostics, and a shift from reactive to preventive care.
  7. Doctors’ roles will evolve into physician-scientists who interpret individual data and guide personalized treatment.
  8. True disruption requires trust, transparency, and policy reform—especially in public health funding and contract accessibility.

Summary:

S. health care system is fundamentally broken by entrenched monopolies, opaque contracts, and broken economic incentives. Mark’s entrepreneurial ventures—offering transparent pricing, direct hospital contracts, local pharmacy access, and affordable drug manufacturing—challenge the status quo by introducing trust, competition, and real-time cost visibility.

A key driver of change is AI, which can analyze complex contracts and reveal hidden price inflation, empowering employers and patients to negotiate better terms. However, AI alone cannot fix systemic issues; structural reforms are essential, including mandatory public disclosure of contracts, greater transparency in hospital and pharmacy pricing, and dismantling vertical integration. The future of health care lies in personalized medicine, AI-driven diagnostics, and preventive models where data is used to tailor treatments.

Doctors will transition from standard care providers to physician-scientists who interpret individual biological data. Ultimately, sustainable disruption requires not just technological innovation, but policy shifts—such as public funding models, guaranteed stop-loss programs, and consumer access to financial assistance—so that health care becomes affordable, transparent, and patient-centered. The greatest opportunity lies in empowering individuals to make informed decisions, leveraging AI and data to break the cycle of hidden costs and inefficiency.

FAQs

The healthcare market is inefficient due to broken economics, lack of competition, and vertical integration among large companies. These entities control pricing through opaque contracts and inter-company transfers, limiting innovation and transparency.

Cost-plus drug pricing introduces transparency by making drug prices publicly available, forcing incumbents to lower prices and compete fairly. This transparency pressures big carriers to respond, creating market shifts and reducing pricing power.

AI can analyze healthcare contracts to identify hidden costs, pricing discrepancies, and unfair terms. This allows employers and consumers to detect overcharges and negotiate better deals, increasing transparency and accountability.

Direct contracting removes intermediaries like PBMs and ASOs, allowing employers to negotiate lower prices, reduce delays, and take responsibility for patient costs—freeing providers from subprime lender risks and increasing trust.

Mark envisions scalable, AI-driven drug manufacturing pods—small, modular facilities that can produce medications locally, reduce costs, and support emergency or niche medical needs, including personalized treatments.

Patients and employers can use AI to analyze contracts, insurance plans, and hospital financial assistance programs. This helps identify cost-saving opportunities, better understand coverage, and avoid overpaying for care.

Chat with AI

Loading...

Pro features

Go deeper with this episode

Unlock creator-grade tools that turn any transcript into show notes and subtitle files.